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Abstract
An important feature of COVID-19, the disease produced by the new coronavirus SARS-CoV-2, 
is the high number of health care workers (HCWs) that acquire the disease. In an initial report of 
138 patients hospitalized with COVID-19 pneumonia in China, 40 patients (29%) were HCWs. 
One reason why HCWs are at higher risk of acquiring COVID-19 is because some patients with 
COVID-19 are admitted to the hospital without the classical presentation, and are therefore not 
tested for the disease early during hospitalization. Presently in the US, it is recommended to 
test for COVID-19 when physicians suspect the disease. This subjective approach may allow 
hospital transmission of COVID-19 from patients without the classical clinical presentation. The 
primary objective of this study is to establish a surveillance system for early identification of 
patients hospitalized with COVID-19 to allow for early implementation of infection control inter-
ventions in an attempt to prevent transmission of COVID-19 to HCWs and other hospitalized 
patients. We are proposing to test all patients who present to the emergency departments and/
or are hospitalized with signs and symptoms of respiratory infection or gastrointestinal infection 
for SARS-CoV-2, regardless of clinical suspicion of COVID-19. Biological samples obtained 
from all patients having symptoms of respiratory or gastrointestinal infection will be tested using 
real-time polymerase chain reaction (RT-PCR) for detection of SARS-CoV-2. Using a robotic 
instrument, the CMP laboratory will be able to test more than 500 samples a day. Data will 
be reported in real-time to participating hospitals for rapid implementation of infection control 
measures.
Introduction and Rationale
The reliability of the healthcare system is a critical component in the fight against new 
pandemics. To have an effective healthcare infrastructure, it is critical to have a healthy 
healthcare workforce. The healthcare workforce encompasses a wide range of profes-
sions and occupations who provide any type of healthcare service, such as physicians, 
nurses, surgeons, dentists, physical and behavior therapists, as well as allied health pro-
fessionals such as respiratory therapists, phlebotomists, medical laboratory scientists, 
dieticians, and social workers. 
An important feature of COVID-19, the disease produced by the new coronavirus SARS-
CoV-2, is the high number of health care workers (HCWs) that acquire the disease. In 
an initial report of 138 patients hospitalized with COVID-19 pneumonia in China, 40 
patients (29%) were HCWs. [1] One reason why HCWs are at higher risk of acquiring 
COVID-19 is because some patients with COVID-19 are admitted to the hospital without 
the classical presentation, and are therefore not tested for the disease early during hos-
pitalization. Wang et al reported one patient admitted to the surgical ward complaining 
of fever, abdominal pain, and diarrhea. This patient infected 10 HCWs from the surgical 
department. [1] 
The concern with the current surveillance system is that patients are tested only when 
clinicians suspect the disease. Patients are suspected to have COVID-19 when they pres-
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Figure 1. Spectrum of disease of patients with COVID-19 (adapted from reference 2).
ent with a syndrome of respiratory infection associated with pneumonia or respiratory failure. Early manifestations of 
COVID-19 may include a syndrome of upper respiratory tract infection, a flu-like syndrome, or a gastrointestinal syn-
drome presenting with diarrhea. [2] (Figure 1) 
In the Louisville Coronavirus Surveillance Program, we are proposing to remove the subjective nature of testing and in-
stead test for SARS-CoV-2 all patients in the emergency department with signs and symptoms of respiratory infection 
or gastrointestinal infection, regardless of clinical suspicion of COVID-19. Some of these patients will be hospitalized 
and others will be discharged home. Some patients are hospitalized as a direct admission from ambulatory settings. 
These patients will be tested in the patient care area after they are hospitalized. We are proposing the implementation 
of this testing in all hospitals in the city of Louisville as part of a comprehensive SARS-CoV-2 surveillance program. 
It is also important to address the concern that HCWs may be afraid to come to work where there is documented hos-
pital transmission of COVID-19.  By having an active surveillance system, it is reasonable to assume that this knowledge 
may serve to make HCWs feel safer than the unknown that is present without this level of comprehensive surveillance. 
Further, this organized approach may serve to minimize unnecessary use of hospital resources such as personal pro-
tective equipment (PPE) as part of incremental testing, as opposed to testing done through a standardized surveillance 
process. 
The information gained through this surveillance system will be used to generate guidelines for real-time hospital and 
community education and response activities. Additionally, data obtained as part of this surveillance will be used to 
produce educational components for a wide range of audiences, including daily multimedia announcements that will 
keep the community up to date on local and reliable COVID-19 information. The lessons learned from this program will 
be immediately transferred to manuscript for submission to peer-reviewed publications with the goal of rapid dissemi-
nation of the knowledge gained from this project. The information will also be shared community-wide through select 
University of Louisville digital channels.
Objectives
Primary objectives
1. To establish a new surveillance system for early identification of hospitalized patients with COVID-19. 
2. To prevent transmission of COVID-19 to health care workers and other hospitalized patients.
Secondary objectives
1. To strengthen existing systems of surveillance for COVID-19. 
2. To better inform Public Health authorities of local COVID-19 activity.
3. To define areas of the community where surveillance activities should be increased. 
4. To identify cases of COVID-19 from emergency departments among patients who may not be hospitalized.
5. To generate educational components and guidelines for real-time hospital and community education and response 
activities.
6. To rapidly disseminate the new knowledge gained by this project.
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An overview of the different components of this project with the most relevant activities for each component is depict-
ed in Figure 2. 
Study Design
Program Overview
This proposal is a collaboration of 1) the Center of Excellence for Research in Infectious Diseases (CERID), University 
of Louisville, 2) the Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), Univer-
sity of Louisville, 3) all hospitals in the city of Louisville, and 4) the Louisville Metro Department of Public Health and 
Wellness. An overview of the program is depicted in Figure 3.
On February 12, 2020 the University of Louisville Regional Biocontainment Laboratory received an isolate of the 
SARS-CoV-2 from the CDC. Investigators from the CPM cultured the virus and started to work on the development of 
real-time polymerase chain reaction (RT-PCR).  
Patients with signs and symptoms of respiratory or gastrointestinal infection seen in one of the ten emergency depart-
ments will be included in the surveillance process. Hospitalized patients directly admitted to the hospital will also be 
included. Samples will be collected as soon as possible and transferred to the CPM laboratory for testing. Three data-
bases will be developed to store project data. Clinical and epidemiological data will be collected by the surveillance 
team and maintained in a REDCap database specifically designed for this purpose. Specimen collected will be retained 
in a biorepository for future testing and a REDCap database will be designed for this purpose. Data from the CPM labo-
Figure 2. The four components of the program with the primary activities for each component.
Figure 3. Overview of the Louisville Coronavirus Surveillance Program. 
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ratory will be collected and maintained in a REDCap database specifically designed for this purpose. All three of these 
REDCap databases will comprise the Comprehensive Surveillance Database for this COVID-19 surveillance program, 
and will be accessible in real-time with secure passwords to all participating institutions, public health authorities, and 
other stakeholders.
Program Advisory Board
An advisory board will be established with the following objectives: 1) To maintain open and consistent communication 
related to the original status of COVID-19 disease; 2) To provide feedback for improvement of the surveillance pro-
gram; and 3) To support the dissemination of information. In addition to public health and other relevant stakeholders, 
the advisory board members may include representation from hospital emergency, infection control, nursing, medical 
staff, and administration departments. Project investigators and members of the advisory board will hold regular meet-
ings to align the course of the project with the COVID-19 epidemic.
Preliminary Studies
The two principal investigators, Drs. Julio Ramirez and Kenneth Palmer, have vast experience in development and im-
plementation of these types of projects. 
Dr. Ramirez is the Chief of the Division of Infectious Diseases and Director of the Center of Excellence for Research in 
Infectious Diseases (ceridlouisville.org). He has led multiple surveillance programs in the State of Kentucky, including 
the Severe Influenza Pneumonia Surveillance (SIPS) Project. SIPS was funded by the Department of Homeland Secu-
rity. [3] He was also funded by the Centers for Disease Control and Prevention to study the role of oseltamivir in hospi-
talized patients with influenza in the city of Louisville. This was done in collaboration of CERID with all adult hospitals 
in Louisville. [4] More recently, Pfizer Pharmaceuticals sponsored CERID to perform a population-based study of all 
hospitalized adult patients in the city of Louisville to define the burden of community-acquired pneumonia. Data from 
this study was used to estimate burden of pneumonia in the United States. [5] The successes of these studies led to the 
selection of CERID as the North American Center of Excellence for Vaccine Epidemiology, funded by Pfizer. This is 
the first such center in the world, and recognizes the unique infrastructure and capabilities of UofL CERID (Center of 
Excellence announcement).
Dr. Kenneth Palmer is the Director of the Center for Predictive Medicine for Biodefense and Emerging Infectious 
Diseases (CPM), and Professor of Pharmacology and Toxicology.  He was trained as a virologist at the University of 
Cape Town, and his research program has focused on development of biologic-based antivirals and vaccines. Q-Grif-
fithsin (Q-GRFT) is a broad-spectrum antiviral protein that was discovered and developed in Dr. Palmer’s laboratory.  
Q-GRFT has been formulated for rectal administration and Dr. Palmer leads an NIH-funded translational research 
program that is testing the product safety in a first-in-humans clinical trial for HIV-1 prevention. [6-8] Dr. Palmer has 
also worked as part of teams that have demonstrated Q-GRFT activity against a broad array of Coronaviruses, including 
SARS-CoV and MERS-CoV.  Dr. Palmer is leading a team of researchers that are now working on developing in vitro 
and in vivo systems for assessing SARS-CoV-2/COVID-19 antiviral and vaccine strategies.
The CV of the two principal investigators are included in Appendices 2 and 3.
Laboratory Methods
Since one of the goals of this study is to define if SARS-CoV-2 is present in different biological samples, specimens 
regularly collected as part of standard of care clinical practice (e.g., respiratory, blood, stool, and urine specimen) will 
be obtained as they are available. The specimen will be transferred from the local hospital to the CERID Biorepository 
Laboratory for labeling and cataloging. Each specimen will be labeled with a Patient Sample ID to maintain privacy, 
while also allowing real-time reporting to a specific hospital. Specimen are transported from the CERID Biorepository 
Lab to the CPM Laboratory for testing.
The CPM laboratory will use the specimen for RNA extraction.  This will involve use of two commercial RNA isolation 
platforms for performance assessment. CPM will also assess two different quantitative reverse transcriptase PCR plat-
forms for SARS-CoV-2 detection.  Once CPM has validated the test outcomes with spiked samples, they will chose a 
single RNA isolation platform and qRT-PCR platform for the surveillance project.
CPM will collect qPCR data, provide an analytical report, and enter the data into the laboratory database. 
Program Coordinating Center
The study will be coordinated by Center of Excellence for Research in Infectious Diseases (CERID). The current struc-
ture of CERID is depicted in Figure 4. 
ULJRI | https://doi.org/10.18297/jri/vol4/iss1/3 5
ULJRI Louisville Coronavirus Surveillance Program
The activities related to this project for each of the CERID units are as follows:
1. Data Management Unit: generate the data collection form and the three REDCap databases, clinical, epidemiolog-
ical, and laboratory, for this project.
2. Implementation Unit: responsible for all surveillance activities, transport of the specimen to the CPM laboratory, 
data collection, and data entry into the REDCap databases.
3. Laboratory Unit: catalog all clinical samples and coordinate with the CPM laboratory for testing.
4. Biorepository Unit will be responsible for maintaining all specimen for future testing and entering data into the 
biorepository database.
5. Quality Assurance Unit will be responsible for monitoring data quality and ongoing process improvement. 
6. Biostatistics Unit will be responsible for periodic and real-time analysis of clinical, epidemiological, and laboratory 
data.
7. Medical Writing Unit will support the generation of manuscripts. 
8. Peer-Review Journals Unit will facilitate rapid publication of new knowledge.
9. Informatics Unit will interface the three databases and generate real-time reports with de-identified information 
about local COVID-19 activity.
10. Community Outreach Unit will be responsible for maintaining open lines of communication with community lead-
ers and coordinating activities of the Advisory Board.
11. University Outreach Unit will be responsible for maintaining open lines of communication with UofL leaders and 
will work with the Community Outreach Unit to coordinate the activities of the Advisory Board.
12. Marketing Unit will collaborate with investigators to develop education and response communications.
Figure 4. Structure of the Project Coordinating Center.
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Protection of Human Participants
All patient information will be entered into REDCap databases, which are HIPAA-compliant. All surveillance informa-
tion is considered protected health information and standard data safety processes will be followed.
Letters of Support
Please see Appendix 4. 
Appendices
All aforementioned appendices are available upon request. Due to formatting constraints, the Journal of Respiratory 
Infections is unable to publish multiple appendices per article.
Appendix 1: List of sub-investigators
Appendix 2: Ramirez CV
Appendix 3:  Palmer CV
Appendix 4: Letters of support
Appendix 5: Proposal budget
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